share_log

Aurora Cannabis to Host Second Quarter 2025 Investor Conference Call

Aurora Cannabis to Host Second Quarter 2025 Investor Conference Call

極光大麻將舉行2025年第二季度投資者電話會議
PR Newswire ·  10/25 05:45

NASDAQ | TSX: ACB

納斯達克|tsx:ACB

EDMONTON, AB, Oct. 24, 2024 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian based leading global medical cannabis company, announced today announced today that it has scheduled a conference call to discuss the results for its second quarter 2025 on Wednesday, November 6, 2024 at 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time. The Company will report its financial results for the second quarter 2025 before the opening of markets that same day.

業務報道,2024年10月24日,位於阿爾伯塔省埃德蒙頓 - 極光大麻股份有限公司(以下簡稱"公司"或"極光")(納斯達克: ACB)(tsx: ACB)是總部位於加拿大的領先全球醫療大麻公司,宣佈今天宣佈,他們已經安排了一個電話會議,討論2025財年第二季度的業績,時間爲2024年11月6日,東部時間上午8:00 | 山區時間上午6:00。該公司將於當天市場開盤前報告2025財年第二季度的財務業績。

Conference Call Details

電話會議詳情

DATE:

Wednesday, November 6, 2024

TIME:

8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time

WEBCAST:

Click Here

日期:

2024年11月6日星期三

時間:

東部時間上午8:00 | 山區時間上午6:00

網絡直播:

點擊這裏

Miguel Martin, Chairman and Chief Executive Officer, and Simona King, Chief Financial Officer, will host the conference call and question and answer period. This weblink has also been posted to the Company's "Investor Info" link at under "Events".

Miguel Martin, 主席兼首席執行官,以及財務長Simona King將主持電話會議和問答環節。該網址也已發佈在公司的「投資者信息」鏈接下的「活動」欄目。

About Aurora Cannabis

關於極光大麻

Aurora is opening the world to cannabis, serving both the medical and consumer markets across Canada, Europe, Australia and South America. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company's adult- use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co, as well as international brands, Pedanios, Bidiol, IndiMed and CraftPlant. Aurora also has a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, wellness and adult recreational markets wherever they are launched. Learn more at and follow us on X and LinkedIn.

極光大麻正在將大麻帶入世界,爲加拿大、歐洲、澳大利亞和南美的醫療和消費市場提供服務。總部位於阿爾伯塔省埃德蒙頓,極光是全球大麻的先驅,致力於幫助人們改善生活。公司的成年用品品牌組合包括Drift、San Rafael '71、Daily Special、Tasty's、Being和Greybeard。醫療大麻品牌包括MedReleaf、CanniMed、極光和Whistler Medical Marijuana Co,以及國際品牌Pedanios、Bidiol、IndiMed和CraftPlant。極光還持有Bevo Farms Ltd.的控股權,這是北美領先的農業植物繁殖供應商。極光以科學和創新驅動,並專注於高質量的大麻產品,其品牌繼續在醫療、健康和成年娛樂市場成爲行業領袖,無論在何處推出。請訪問網站 了解更多信息,並在X和LinkedIn上關注我們。

Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".

Aurora的普通股在納斯達克和tsx上交易,代碼爲「ACB」。

For Media:

For Investors:

Michelle Lefler

ICR, Inc.

VP, Communications & PR

Investor Relations

[email protected]

[email protected]

媒體資訊:

對於投資者:

米歇爾·萊夫勒

Tom Filandro

通信與公關副總裁

投資者關係

[email protected]

[email protected]

Forward Looking Statements

前瞻性聲明

This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the timing for the release of the Company's Fiscal 2025 Q2 financial statements and the conference call to discuss the results.

本新聞發佈包含特定「前瞻性信息」,根據適用證券法的含義(「前瞻性聲明」)。前瞻性聲明經常以諸如「計劃」,「繼續」,「預期」,「項目」,「打算」,「相信」,「預測」,「估計」,「可能」,「將」,「潛在」,「提議」等類似字詞,或陳述某些事件或狀況「可能」或「將」發生。本新聞發佈中的前瞻性聲明包括但不限於有關公司財政2025年Q2財務報表發佈時間和電話會議討論結果的表述。

These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations (with respect to the Transaction and more generally with respect to future acquisitions), management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 20, 2024 (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

這些前瞻性聲明僅爲預測。本新聞稿中包含的前瞻性信息或聲明是基於管理層認爲合理的假設而制定的。制定前瞻性聲明所涉及的主要因素或假設包括,但不限於,政府來源公開可用信息,市場研究和行業分析的信息以及公司基於對該行業的數據和了解的合理假設。前瞻性聲明受到各種風險、不確定性和其他因素的影響,管理層認爲在相應的情況下是相關且合理的,可能導致實際事件、結果、活動水平、業績、前景、機會或成就與前瞻性聲明中預測的有着重大差異。這些風險包括但不限於保留關鍵人員的能力、繼續投資支持增長的基礎設施的能力、以可接受的條件獲得融資的能力、產品的持續質量、顧客體驗和保留、第三方政府和非政府消費者銷售渠道的發展、公司對加拿大和出口地區的消費者需求估計、對未來結果和費用的預期、成功整合收購的業務和運營風險(就交易和更普遍地進行的未來收購而言)、對銷售渠道擴展和維持分銷能力的能力、競爭對市場環境的總體影響、大麻種植業務的產量、產品需求、所需商品價格的變動、競爭以及行業法規政策的可能變更,流行病、大流行或其他公共衛生危機等風險、不確定性和因素,以及在公司2024年6月20日的年度信息(「AIF」)中列出的「風險因素」標題下的其他風險、不確定性和因素,該公司已向加拿大證券監管機構進行了披露,並可在SEDAR+上查看該公司的發行人簡介,也已在美國證券交易委員會(SEC)的網站www.sec.gov上進行了披露。本公司提醒讀者,在評估前瞻性聲明時要謹慎考慮所述的風險、不確定性和假設,並告誡讀者不要過分依賴此類信息。本公司沒有義務,也明確否認任何更新或修訂任何前瞻性聲明的意圖或義務,除非根據適用的證券法明確要求。

SOURCE Aurora Cannabis Inc.

極光大麻公司簡介

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

想要您公司的新聞在PRNEWSWIRE.COM上特色呈現嗎?

440k+
440k+

Newsrooms &
新聞發佈室&

Influencers
影響力人士
9k+
9k+

Digital Media
數字媒體

Outlets
Outlets
270k+
270k+

Journalists
新聞記者

Opted In
Opted In
GET STARTED
開始使用

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論